Human Multipotent Adipose-Derived Stem (hMADS) were isolated from donor adipose tissue and extensively studied by the academic research laboratory managed by ExAdEx-Innov co-founder and Scientific Advisor Christian Dani, PhD, and Director of Research at INSERM, co-inventor of the patents covering their application.
hMADS cells are a powerful 2D tool for screening of compounds in a standardized, time-effective and cost-effective manner, that perfectly complements ExAdEx 3D real human fat tissue organoids, for a comprehensive investigation on adipose tissue from screening up to mechanistic studies.
White adipocytes derived from hMADS can switch to a brown adipocyte phenotype that is associated with an increased energy expenditure. hMADS can thus be used to screen for drugs and active ingredients stimulating energy expenditure capacity, which could help to dissipate excess caloric intake in several clinical applications (nutrition, pharmaceutical approaches, cosmetics).
ExAdEx-Innov Drives Innovation in Cosmetic Industry: Contributing to the Development of VividEye™ from Mibelle Biochemistry We are thrilled to announce ExAdEx-Innov’s contribution to the research
Our Collaboration with Exsymol Monaco at the 34th Congress IFSCC Brazil 2024 We are excited to announce that our scientific research work performed in collaboration
Let’s explore innovation at the 10th edition of COSMETIC 360 tradeshow in Paris in October 2024! We are pleased to announce our participation in the
Copyright © 2022 ExAdEx-Innov All rights reserved
KOL on adipose tissue biology.
Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice).
Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program).
Co-inventor of 5 patents
Expert in clinical applications of adipose tissue.
Plastic Reconstructive and Aesthetic Surgeon in Nice.
Member of the Medical Council of Alpes Maritimes region.
Expert for the French National Regulatory Agency ANSM for medical devices.
Certified by French Health Autority HAS (2020-2024).
PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.
Expert in cell therapy and immunology.
Senior Lecturer (Maitre de conférences).
Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).
Director of « Micoralis » research team at Université Côte d’Azur (Nice).
Founder and CEO of the biotech company Biointerférence (2003-2006).
Co-inventor of 5 patents.
Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.
With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov.
In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille).
He is co-inventor of the 2 company’s patent families.
Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue.
Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.
With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years.
He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.
Main areas of expertise: Biotech Startup Business Development; Project management
